Market research
IDRA Idera Pharmaceuticals Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 27M
- P/E ratio
- Not available
- Analyst target
- 1
- Dividend yield
- 0.0%
- Beta
- 1.3
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US45168K4058
- Market cap
- 27M
- P/E ratio
- Not available
- Analyst target
- 1
- Dividend yield
- 0.0%
- Beta
- 1.3
About
About Idera Pharmaceuticals Inc
Idera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration agreement with Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the IDRA discussion.
5 years, 4 months ago
Idera Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 61.7% below its 200 day moving average.
From a valuation standpoint, the stock is 96.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 42.1.
Idera Pharmaceuticals, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 230.2% to $-77M since the same quarter in the previous year.
Finally, its free cash flow grew by 26.7% to $-8M since the same quarter in the previous year.
Based on the above factors, Idera Pharmaceuticals, Inc gets an overall score of 2/5.